# Dendreon clinical trials: 20 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Dendreon as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dendreon: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/dendreon

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2023 | NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Dendreon | Phase 2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06134232) |
| September 27, 2018 | NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer | Dendreon | Phase 3 | Completed | Adenocarcinoma of the Prostate | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03686683) |
| November 11, 2013 | NCT01981122 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | Dendreon | Phase 2 | Completed | Metastatic Prostate Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01981122) |
| November 11, 2013 | NCT01981109 | Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer | Dendreon | Observational | Terminated | Castration-Resistant Prostate Cancer | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01981109) |
| November 15, 2012 | NCT01727154 | Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T | Dendreon | Observational | Terminated | Prostate Cancer | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01727154) |
| December 8, 2011 | NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | Dendreon | Phase 2 | Completed | Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01487863) |
| November 23, 2011 | NCT01477749 | Sipuleucel-T Manufacturing Demonstration Study | Dendreon | Phase 2 | Completed | Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate... | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01477749) |
| September 9, 2011 | NCT01431391 | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | Dendreon | Phase 2 | Completed | Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01431391) |
| May 13, 2011 | NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | Dendreon | Phase 2 | Terminated | Urothelial Carcinoma | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01353222) |
| April 19, 2011 | NCT01338012 | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer | Dendreon | Phase 2 | Terminated | Prostate Cancer | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01338012) |
| March 2, 2011 | NCT01306890 | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer | Dendreon | Observational | Completed | Advanced Prostate Cancer, Prostatic Neoplasms | 1,976 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01306890) |
| May 31, 2010 | NCT01133704 | Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer | Dendreon | Phase 3 | Completed | Hormone-Refractory Prostate Cancer | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01133704) |
| May 13, 2009 | NCT00901342 | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | Dendreon | Phase 2 | Completed | Prostate Cancer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00901342) |
| February 23, 2009 | NCT00849290 | Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) | Dendreon | Phase 2 | Completed | Metastatic Androgen Independent Prostate Cancer | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00849290) |
| February 9, 2009 | NCT00839631 | Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors | Dendreon | Phase 1 | Completed | Solid Tumors | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00839631) |
| October 24, 2008 | NCT00779402 | PROvenge Treatment and Early Cancer Treatment | Dendreon | Phase 3 | Completed | Prostate Cancer | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00779402) |
| July 15, 2008 | NCT00715104 | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer | Dendreon | Phase 2 | Completed | Prostate Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00715104) |
| July 15, 2008 | NCT00715078 | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | Dendreon | Phase 2 | Completed | Prostate Cancer | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00715078) |
| March 5, 2004 | NCT00005947 | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | Dendreon | Phase 3 | Completed | Prostate Cancer | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005947) |
| July 24, 2003 | NCT00065442 | Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | Dendreon | Phase 3 | Completed | Prostate Cancer | 512 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00065442) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 11 |
| Phase 3 | 5 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 4 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Prostatic Neoplasms | 13 |
| Neoplasms | 3 |
| Genital Neoplasms, Male | 1 |
| Urogenital Neoplasms | 1 |
| Prostatic Diseases | 1 |
| Adenocarcinoma | 1 |
| Carcinoma | 1 |
| Neoplasms, Glandular and Epithelial | 1 |
| Carcinoma, Transitional Cell | 1 |
| Urinary Bladder Neoplasms | 1 |
| Ureteral Neoplasms | 1 |
| Urethral Neoplasms | 1 |
| Neoplasms by Site | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
- [Translation companies in the United States](https://specstream.ai/data/businesses/translation-companies/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [B2B scientific equipment companies in the United States](https://specstream.ai/data/businesses/b2b-scientific-equipment-companies/united-states)
